Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

Biochemical Pharmacology

Volumn 51, Issue 7, 1996, Pages 949-956

  Barnette, Mary S ^a   O'Leary Bartus, Joan ^a   Burman, Miriam ^a   Christensen, Siegfried B ^a   Cieslinski, Lenora B ^a   Esser, Klaus M ^a   Prabhakar, Uma S ^a   Rush, Julia A ^a   Torphy, Theodore J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

monocyte; myeloperoxidase; neutrophil; phosphodiesterase; rolipram binding; tumor necrosis factor alpha

Indexed keywords

1 (4 ACETAMIDOBENZYL) 3 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 2 PYRROLIDINONE; 1 (4 AMINOBENZYL) 4 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL 2 PYRROLIDINONE; 1 (4 AMINOBENZYL) 4 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 2 IMIDAZOLIDINONE; 1 (4 PYRIDINYLBENZYL) 3 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 2 PYRROLIDINONE; 4 CYANO 4 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL)CYCLOHEXANONE; ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; RADIOLIGAND; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; BRAIN MICROSOME; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DEGRANULATION; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MONOCYTE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT;

EID: 0029939872     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00053-6     Document Type: Article

References (34)

1. Busse WW and Anderson CL, The granulocyte responses to the phosphodiesterase inhibitor RO 20-1724. J Allergy Clin Immunol 67: 70-74, 1981.
2. Elliott KRF and Leonard EJ, Interaction of formylmethionylleucyl-phenylalanine, adenosine and phosphodiesterase inhibitors in human monocytes. FEBS Lett 254: 94-98, 1989.
3. Nielson CP, Vestal RE, Sturm RJ and Heaslip R, Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 86: 801-808, 1990.
4. Peachell PT, Undem BJ, Schleimer RP, MacGlashan DW, Lichtenstein LM, Cieslinski LB and Torphy TJ, Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 148: 2503-2510, 1992.
5. Prabhakar U, Lipshutz D and Truneh A, Inhibition of CD44, CD45, and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifylline. Int J Immunopharmacol 15: 205-209, 1993.
6. 1. Naunyn Schmiedebergs Arch Pharmacol 344: 682-690, 1991.
7. Semmler J, Wachtel H and Endres S, The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 15: 409-413, 1993.
8. Horowski R and Sastre-Y-Hernandez M, Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Curr Therap Res 38: 23-29, 1985.
9. Brunnee T, Engelstatter R, Steinijans VW and Kunkel G, Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 5: 982-985, 1992.
10. Wachtel H, Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22: 267-272, 1983.
11. Wachtel H, Characteristic behavioral alteration in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77: 309-316, 1982.
12. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR and Livi GP, Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267: 1798-1804, 1992.
13. m, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. J Biol Chem 268: 6470-6476, 1993.
14. Souness JE, Malsen C and Scott LC, Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase. FEBS Lett 302: 181-184, 1992.
15. Torphy TJ, DeWolf WE Jr, Green DW and Livi GP, Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions Suppl 43: 51-71, 1993.
16. Schmiechen R, Schneider HH and Wachtel H, Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology 102: 17-20, 1990.
17. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB and Torphy TJ, Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in isolated rabbit gastric glands: Correlation between function and interaction with a high affinity rolipram-binding site. J Pharmacol Exp Ther 273: 1396-1402, 1995.
18. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM and Torphy TJ, Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 266: 306-313, 1993.
19. Prabhakar U, Lipshutz D, O'Leary Bartus J, Slivjak MJ, Smith EF III and Esser KM, Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 16: 805-816, 1994.
20. Semmler J, Gerbert U, Eisenhut T, Moeller J, Schonharting MM, Allera A and Endress S, Xanthine derivatives: Comparison between suppression of tumour necrosis factor α production and inhibition of cAMP phosphodiesterase activity. Immunology 78: 520-525, 1993.
21. Nourshargh S and Hoult JRS, Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors. Eur J Pharmacol 122: 205-212, 1986.
22. Colotta F, Peri G, Villa A and Mantovani A, Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. J Immunol 132: 936-944, 1984.
23. Winston SE, Fuller SA and Hurrel JGR, Enzyme linked immunosorbent assay (ELISA) for detection of antigens. In: Current Protocols in Molecular Biology (Eds. Ausubel FM, Brente R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K), P. 11.2.1. John Wiley, New York, 1987.
24. Köhler G and Milstein C, Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
25. Davis CW and Daly JW, A simple direct assay of 3′,5′-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-boronate affinity gel chromatography. J Cyclic Nucleotide Res 5: 65-74, 1979.
26. m, rolipram-sensitive cyclic AMP phosphodiesterase. Mol Cell Biol 10: 2678-2686, 1990.
27. Schade FU and Schudt C, The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 230: 9-14, 1993.
28. Molnar-Kimber K, Yonno L, Heaslip R and Weichman B, Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39: C77-C79, 1993.
29. Schneider HH, Schmiechen R, Brezinski M and Seidler J, Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127: 105-115, 1986.
30. Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB and Torphy TJ, The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase catalytic activity. J Pharmacol Exp Ther 273: 674-678, 1995.
31. Bolger G, Michaeli T, Martins T, St. John T, Steiner B, Rodgers L, Riggs M, Wigler M and Ferguson K, A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13: 6558-6571, 1993.
32. Obernolte R, Bhakta S, Alvarez R, Bach C, Zuppan P, Mulkins M, Jarnagin K and Shelton ER, The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene 129: 239-247, 1993.
33. Engels P, Fichtel K and Lubbert H, Expression and regulation of human rat phosphodiesterase type IV isogenes. FEBS Lett 350: 291-295, 1994.
34. m cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther 251: 199-206, 1989.